scholarly journals Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

2016 ◽  
Vol Volume 9 ◽  
pp. 3771-3781 ◽  
Author(s):  
Xiao-Qun Liu ◽  
Xiangdong Liu ◽  
Tiankui Qiao ◽  
Wei Chen ◽  
Sujuan Yuan
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Controlled Trials ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
Randomized Controlled ◽  
Locally Recurrent ◽  
First Line Treatment

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

2012 ◽  
Vol 12 (5) ◽  
pp. 322-330 ◽  
Author(s):  
Rachel Borson ◽  
Graydon Harker ◽  
James Reeves ◽  
Thaddeus Beck ◽  
Steven Hager ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Line Treatment ◽  
First Line ◽  
Locally Recurrent ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document